U.S. markets open in 2 hours 1 minute

D8 Holdings Corp. (DEH)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
9.93+0.05 (+0.51%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close9.88
Bid0.00 x 3200
Ask9.95 x 900
Day's Range9.87 - 9.93
52 Week Range9.60 - 10.60
Avg. Volume424,575
Market Cap428.231M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Becton Dickinson Backing Vicarious Surgical’s D8 SPAC Deal

    Becton Dickinson Backing Vicarious Surgical’s D8 SPAC Deal

    (Bloomberg) -- Medical technology giant Becton Dickinson & Co., billionaire Bill Gates and Khosla Ventures are among investors backing robotics startup Vicarious Surgical Inc.’s merger with special purpose acquisition company D8 Holdings Corp.The transaction gives the combined entity an enterprise value of about $1.1 billion, the companies said, confirming an earlier Bloomberg News report.In addition to Becton Dickinson, Gates and Khosla, other investors set to participate in the deal’s $115 million private investment in public equity, or PIPE, include former Google CEO Eric Schmidt’s Innovation Endeavors and E15 VC, a venture firm. Bloomberg last month reported that Vicarious and D8 were in merger talks.Charlestown, Massachusetts-based Vicarious, led by Chief Executive Officer Adam Sachs, develops robotics technology with the aim of improving patient outcomes and the efficiency of surgical procedures, while reducing overall health-care costs. Sachs founded the company with Sam Khalifa, its chief technology officer, and Barry Greene, a bariatric and general surgeon, and management will remain in place following the D8 deal.Vicarious, whose technology has been granted “breakthrough device” designation by the U.S. Food and Drug Administration, is expected to have more than $425 million in cash following the transaction, and estimated 2025 revenues of $355 million.Hong Kong-based D8’s president Donald Tang will join Vicarious’ board, alongside AIDS researcher David Da-I Ho. The deal is expected to close in the third quarter. Once it is complete, Vicarious is set to trade on the New York Stock Exchange under the symbol RBOT.Surgical RobotsD8 was “blown away” by Vicarious’s technology, Tang said in an interview. “After doing due diligence, we were floored by what’s possible in terms of stabilizing surgical procedures,” he said, adding that D8 will seek to leverage its relationships in Asia and elsewhere to help Vicarious expand outside the U.S.A SPAC merger is the “right path” for Vicarious, Sachs said, as the deal bolsters its cash balance by as much as $345 million without the company having to raise multiple private rounds of funding. “As we move to commercialize our product, being public gives us a level of credibility we may not have had as a private company,” he said.The company is expected to produce its first year of revenue in 2023 and Sachs said its low cost basis will help its products gain traction. He estimates that Vicarious’ technology, which can be inserted into a patient’s body through a 1.5 centimeter incision, is five to ten times cheaper than legacy surgical robots.(Updates throughout with confirmation of earlier report.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • How Many D8 Holdings Corp. (NYSE:DEH) Shares Do Institutions Own?
    Simply Wall St.

    How Many D8 Holdings Corp. (NYSE:DEH) Shares Do Institutions Own?

    The big shareholder groups in D8 Holdings Corp. ( NYSE:DEH ) have power over the company. Institutions often own shares...

  • Bill Gates-Backed Vicarious Is in Talks to Merge With D8 SPAC

    Bill Gates-Backed Vicarious Is in Talks to Merge With D8 SPAC

    (Bloomberg) -- Vicarious Surgical, a developer of medical robot technology that’s backed by Microsoft Corp. co-founder Bill Gates, is in talks to go public through a merger with blank check-firm D8 Holdings Corp., according to a person with knowledge of the matter.The companies are discussing a deal that values the combined entity at about $1.1 billion, said the person, who asked not to be identified because the talks are private. Terms aren’t final and it’s possible talks could fall apart.Representatives for Vicarious and D8 didn’t immediately respond to requests for comment.Charlestown, Massachusetts-based Vicarious Surgical, co-founded by Adam Sachs, Sammy Khalifa and Dr. Barry Greene in 2014, touts minimally invasive surgery using proprietary human-like surgical robots and virtual reality. Along with Gates, investors include E15 Capital, Khosla Ventures, Innovation Endeavors and AME Cloud Ventures.Hong Kong-based D8, led by CEO David Chu and President Donald Tang, raised $345 million in a July initial public offering.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.